Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines.
About Us
We strive to provide hope to patients with genomically defined cancers by delivering bold, precise and innovative medicines.
We are a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective SMARCA2 and KAT6A degraders. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (“Precision ADCs”) with partners and advancing additional programs in discovery. We are on a mission to extend the promise of precision medicine to every cancer patient in need.
